220230-97-7Relevant academic research and scientific papers
"Double-concave" graphene: Permethoxylated hexa-peri- hexabenzocoronene and its cocrystals with hexafluorobenzene and fullerene
Wang, Zhaohui,Doetz, Florian,Enkelmann, Volker,Muellen, Klaus
, p. 1247 - 1250 (2005)
Extremely nonplanar permethoxylated hexa-peri-hexabenzocoronene can be prepared by using a facile ferric chloride cyclodehydrogenation procedure. The combination of a rigid "double-concave" aromatic core with 18 flexible methoxy groups at the periphery ma
Space-conjugated organic molecule based on hexaarylbenzene skeleton and preparation and application thereof
-
Paragraph 0050; 0053; 0054, (2018/11/22)
The invention belongs to the technical field of organic electronics, and discloses a space-conjugated organic molecule based on a hexaarylbenzene skeleton and preparation and application thereof. Thespace-conjugated organic molecular structure based on th
Total syntheses of ningalin A, lamellarin O, lukianol A, and permethyl storniamide A utilizing heterocyclic azadiene Diels - Alder reactions
Boger, Dale L.,Boyce, Christopher W.,Labroli, Marc A.,Sehon, Clark A.,Jin, Qing
, p. 54 - 62 (2007/10/03)
Concise, efficient total syntheses of ningalin A (1), lamellarin O (2), lukianol A (3), and permethyl storniamide A (5) are detailed on the basis of a common heterocyclic azadiene Diels-Alder strategy (1,2,4,5-tetrazine → 1,2-diazine → pyrrole) ideally suited for construction of the densely functionalized pyrrole cores found in the three classes of marine natural products. Examination of the natural products and a number of synthetic intermediates revealed that some including lamellarin O (2) and lukianol A (3) exhibit modest cytotoxic activity against both wild-type and multidrug- resistant tumor cell lines. Fundamentally more important, a new class of agents including permethyl storniamide A (5) and its precursor 30, which lack inherent cytotoxic activity, are disclosed which reverse the multidrug- resistant (MDR) phenotype, resensitizing a human colon cancer cell line (HCT116/VM46) to vinblastine and doxorubicin at lower doses than the prototypical agent verapamil.
